CY1122473T1 - Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης - Google Patents

Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης

Info

Publication number
CY1122473T1
CY1122473T1 CY20191101366T CY191101366T CY1122473T1 CY 1122473 T1 CY1122473 T1 CY 1122473T1 CY 20191101366 T CY20191101366 T CY 20191101366T CY 191101366 T CY191101366 T CY 191101366T CY 1122473 T1 CY1122473 T1 CY 1122473T1
Authority
CY
Cyprus
Prior art keywords
tablet
salized
high dose
dose optimized
mid
Prior art date
Application number
CY20191101366T
Other languages
English (en)
Inventor
Rudolph WILHELM
Markus PRÖLS
Roland Greinwald
Tanju NACAK
Original Assignee
Dr. Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Falk Pharma Gmbh filed Critical Dr. Falk Pharma Gmbh
Publication of CY1122473T1 publication Critical patent/CY1122473T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Η παρούσα εφεύρεση αφορά από το στόματος, ανθεκτικό έναντι γαστρικού υγρού, δισκίο υψηλής δόσης που περιλαμβάνει μεσαλαζίνη ως δραστικό συστατικό, καθώς και τη χρήση αυτού.
CY20191101366T 2015-10-30 2019-12-20 Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης CY1122473T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15192269.7A EP3162362A1 (de) 2015-10-30 2015-10-30 Optimierte mesalazinhaltige hochdosistablette
PCT/EP2016/075427 WO2017072050A1 (de) 2015-10-30 2016-10-21 Optimierte mesalazinhaltige hochdosistablette

Publications (1)

Publication Number Publication Date
CY1122473T1 true CY1122473T1 (el) 2021-01-27

Family

ID=54476727

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101366T CY1122473T1 (el) 2015-10-30 2019-12-20 Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης

Country Status (21)

Country Link
US (1) US11135159B2 (el)
EP (2) EP3162362A1 (el)
JP (1) JP6872135B2 (el)
KR (1) KR20180077246A (el)
CN (2) CN117180218A (el)
AU (1) AU2016347352B2 (el)
CA (1) CA3001435A1 (el)
CY (1) CY1122473T1 (el)
DK (1) DK3368017T3 (el)
EA (1) EA201890828A1 (el)
ES (1) ES2761319T3 (el)
HK (1) HK1255193A1 (el)
HR (1) HRP20192184T1 (el)
HU (1) HUE046593T2 (el)
LT (1) LT3368017T (el)
MX (1) MX2018005358A (el)
PL (1) PL3368017T3 (el)
PT (1) PT3368017T (el)
RS (1) RS59748B1 (el)
SI (1) SI3368017T1 (el)
WO (1) WO2017072050A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162293A1 (it) * 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
TR201722039A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mesalazi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3662895A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CA2444814C (en) * 2001-10-24 2009-06-09 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
PT1453487E (pt) * 2001-11-23 2008-05-13 Procter & Gamble Forma de dosagem farmacêutica com revestimentos múltiplos
DK1519717T3 (da) * 2002-07-05 2011-01-10 Temrel Ltd Sammensætning til kontrolleret frisætning
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
WO2009047802A2 (en) * 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
US9463163B2 (en) * 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
ES2821766T3 (es) * 2013-02-22 2021-04-27 Zeria Pharm Co Ltd Comprimido con recubrimiento entérico
KR102174942B1 (ko) * 2013-10-29 2020-11-06 틸로츠 파마 아게 지연 방출 약물 제형
IN2014MU00097A (el) * 2014-01-10 2015-08-21 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
SI3368017T1 (sl) 2020-01-31
CA3001435A1 (en) 2017-05-04
HUE046593T2 (hu) 2020-03-30
EA201890828A1 (ru) 2018-11-30
AU2016347352B2 (en) 2021-09-09
US11135159B2 (en) 2021-10-05
WO2017072050A1 (de) 2017-05-04
MX2018005358A (es) 2018-06-06
JP2018531960A (ja) 2018-11-01
HRP20192184T1 (hr) 2020-03-06
KR20180077246A (ko) 2018-07-06
CN117180218A (zh) 2023-12-08
EP3368017A1 (de) 2018-09-05
PL3368017T3 (pl) 2020-04-30
JP6872135B2 (ja) 2021-05-19
ES2761319T3 (es) 2020-05-19
CN108348472A (zh) 2018-07-31
HK1255193A1 (zh) 2019-08-09
AU2016347352A1 (en) 2018-05-10
RS59748B1 (sr) 2020-02-28
US20180311155A1 (en) 2018-11-01
EP3162362A1 (de) 2017-05-03
DK3368017T3 (da) 2019-12-16
EP3368017B1 (de) 2019-11-06
PT3368017T (pt) 2020-01-06
LT3368017T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MA42303A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
CY1121171T1 (el) Πυρογλουταμικη βορτιοξετινη
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MA49837A (fr) Compositions pharmaceutiques
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων